Welcome to our dedicated page for Dentsply Sirona SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DENTSPLY SIRONA Inc. (Nasdaq: XRAY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, strategic reviews and key governance decisions.
In its Form 8-K filings, Dentsply Sirona reports results of operations and financial condition for recent quarters, including segment and geographic performance, non-GAAP metrics and information about goodwill and intangible asset impairments. The company also files 8-Ks to disclose changes in executive officers, retention equity incentive awards, formation of board-level committees and updates on matters such as the conclusion of an SEC Division of Enforcement investigation without enforcement action.
Other filings referenced by the company, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, contain detailed risk factors, financial statements and management discussion that are incorporated by reference in forward-looking statements. These documents provide context on how Dentsply Sirona views risks related to its dental products, technologies, segments and global operations.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the significance of each document in straightforward language. Real-time updates from EDGAR help users follow new 8-Ks reporting quarterly earnings, leadership transitions or strategic portfolio decisions, as well as periodic reports like 10-K and 10-Q when available. For those monitoring governance and incentives, filings also describe compensation arrangements, retention grants and board committee structures. This page is a focused resource for understanding how Dentsply Sirona communicates material information, manages regulatory obligations and frames risks and opportunities in its official SEC documents.
Dentsply Sirona reported Q1 2026 results showing flat sales but weaker profitability while reiterating its full-year outlook. Net sales were $880 million versus $879 million a year ago, but GAAP results swung to a net loss of $10 million, or ($0.05) per share, from earnings of $20 million, or $0.10 per share.
On a non-GAAP basis, adjusted EPS was $0.27, down from $0.44, and adjusted EBITDA fell to $129 million with margin declining to 14.7% from 19.0%. Constant currency sales decreased 6.7% as growth in Wellspect Healthcare offset softer trends in Orthodontic and Implant Solutions and Essential Dental Solutions.
Operating cash flow improved to $40 million from $7 million, while free cash flow remained at negative $12 million. Cash and cash equivalents were $190 million and total equity was $1.3 billion as of March 31, 2026. The company highlighted the launch of its AI-enabled Smart View‑Detect diagnostic aid, new distribution agreements, and ongoing restructuring and capital allocation efforts, and maintained 2026 guidance for net sales of $3.5–$3.6 billion and adjusted EPS of $1.40–$1.50.
DENTSPLY SIRONA Inc (Common Stock, CUSIP 24906P109) is reported in a Schedule 13G by Vanguard Capital Management. The filing states Vanguard beneficially owns 10,529,427 shares, representing 5.27% of the class. The filer reports 1,529,870 shares of sole voting power and 10,529,427 shares of sole dispositive power. The filing lists Vanguard's Malvern, PA address and is signed by Ashley Grim, Head of Global Fund Administration, dated 04/29/2026.
Vanguard Portfolio Management reports beneficial ownership of 10,724,505 shares of DENTSPLY SIRONA Inc. (Common Stock, CUSIP 24906P109), representing 5.36% of the class as of 03/31/2026. The filing shows sole voting power for 193,759 shares and sole dispositive power for 10,724,505 shares. The Schedule 13G was signed on 04/29/2026 by Ashley Grim, Head of Global Fund Administration, and discloses holdings held or managed across Vanguard affiliates and client accounts.
DENTSPLY SIRONA Inc. is calling a virtual 2026 Annual Meeting of Stockholders on June 2, 2026 at 8:00 a.m. Eastern Time. Stockholders of record on April 6, 2026, representing 200,320,502 common shares, can vote online, by phone, by mail, or during the webcast.
They will vote on electing twelve directors, ratifying Deloitte & Touche LLP as independent auditors for 2026, approving 2025 executive compensation on a non-binding basis, and amending the 2024 Omnibus Incentive Plan to increase the common stock issuable under the plan by 15,000,000 shares.
MAZELSKY JONATHAN JAY reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky received a grant of phantom stock under the Directors' Deferred Compensation program. The award covers 2,644.6402 phantom stock units at an economic reference price of $11.34 per unit, each tied to one share of common stock.
Following this compensation grant, his balance in this phantom stock account increased to 17,179.8540 units. According to the terms, these phantom stock units are economically equivalent to common shares and will be settled in common stock after his termination of service as a director.
DENTSPLY SIRONA Inc ownership update: The Vanguard Group filed an Amendment No. 18 to a Schedule 13G/A reporting 0 shares beneficially owned and 0% of the class. The filing explains an internal realignment at The Vanguard Group that disaggregated certain subsidiaries for separate reporting in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration, and lists Vanguard's registered address in Malvern, Pennsylvania.
Southpoint Master Fund, LP and affiliated filers reported beneficial ownership of 10,000,000 shares of Dentsply Sirona Inc. Common Stock (CUSIP 24906P109), representing 5.0% of the class. The shares are reported as held with shared voting and shared dispositive power of 10,000,000.
The filing is a joint Schedule 13G listing Southpoint Master Fund, LP; Southpoint Capital Advisors LP; Southpoint Capital Advisors LLC; Southpoint GP, LP; Southpoint GP, LLC; and John S. Clark II as reporting persons. The ownership percentages are calculated using 199,749,333 shares outstanding as of February 20, 2026.
Scavilla Daniel T reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. reported that President and CEO Daniel T. Scavilla received a grant of 3,554.869 shares of phantom stock under a Supplemental Executive Retirement Plan. The phantom stock has an economic value equivalent to common stock at a reference price of $11.43 per share.
The award represents a SERP contribution for the year 2025 based on the 12/31/25 closing price and is held as a derivative interest. These phantom shares will be settled in common stock upon the executive’s termination of employment, and there were 3,554.869 phantom stock units reported as held directly after this grant.